|
**Overview**: Immune Deficiency CD3 Panel**Introduction**: The Immune Deficiency CD3 Panel is a diagnostic tool designed to assess CD3 cell population using whole blood samples. In India, T-cell deficiencies (SCID, DiGeorge, HIV) are major causes of severe infections in children, with CD3 as pan-T-cell marker essential for evaluating T-cell lymphopenia. High morbidity from under-testing in rural/low-SES infants with recurrent/persistent infections, limited flow labs, delayed HSCT or prophylaxis leading to early mortality. Per immunology practices aligned with ICMR and Indian Society for Primary Immune Deficiency guidelines, the test employs flow cytometry for CD3 count, total lymphocytes, and T-cell profile over 1-2 days with high accuracy, valuable for screening T-cell immunodeficiency. This diagnostic falls under immune profiling and targets infants/children with failure to thrive or opportunistic infections, addressing accurate detection to guide further subset analysis or transplant referral. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early T-cell assessment and reducing infection mortality. Its whole blood-based approach ensures reliable T-cell enumeration.**Other Names**: Imm Def CD3 Pnl.**FDA Status**: FDA approved, CLIA certified for hematology/immunology, compliant with 2025 standards.**Historical Milestone**: CD3 flow standard; in India, used in PID/HIV workup.**Purpose**: The test assesses 3 parameters including CD3 count to guide immune deficiency evaluation, assess T-cell population, inform management.**Test Parameters**: 1. CD3 Count, 2. Total Lymphocytes, 3. T-Cell Profile.**Pretest Condition**: No fasting required; patients should report recurrent infections.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for flow).**Medical History**: Patients should provide details on infection type, growth, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed T-cell defect including mortality, benefits of profiling, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using flow cytometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low lymphocyte count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Low CD3 indicates T-cell deficiency, necessitating specialist input.**Specialist Consultation**: Immunologists should be consulted for management.**Additional Supporting Tests**: CD4/CD8 subsets, genetic testing for confirmation.**Test Limitations**: Requires viable cells; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, PID Studies India 2023. |
